• slide1b

  • slide2b

  • slide3b

Trials We Have Funded

Trials We Have Funded

In order to live up to our mission of eradicating cancer through funding research, Pierce Phillips Charity focuses a great deal of attention and resources towards funding clinical trials that have significant impact potential for children fighting cancer today.

Pierce Phillips Charity makes every effort to select the most forward thinking and novel approaches to treating the most aggressive forms of childhood cancer. Since 2010, Pierce Phillips Charity has funded 4 trials at 11 of the top research centers.

Currently, Pierce Phillips Charity is reviewing proposals from many top rated research institutions for a pilot study in a previously unaddressed area of Neuroblatoma treatment.  This study will specifically look at children with a non-resectable bulky tumor that has either resisted chemotherapy or is a local relapse. This particular study is very close to the heart for us at PPC because this presentation in particular is what Pierce faced, and there are currently no viable options to treat these cases.  A breakthrough in this area would be groundbreaking in the childhood cancer community.

Below is a summary of the trials Pierce Phillips Charity is currently funding:

  • Dendritic Cell Vaccine- Penn State Children’s, Dana Farber Cancer center Boston Children’s Kenneth Lucas MD
  • Rapamycin + VBL- The Hospital for Sick Children Toronto, University of Vermont, Riley’s Children’s Hospital San Diego Sylvain Baruchel MD and Giselle Sholler MD
  • JX-594- Cincinnati Children’s Hospital, Texas Children’s Cancer Center at Baylor, Nationwide Children’s Hospital Columbus, Ohio Timothy Cripe MD and Chrystal Louis MD
  • ACT FAST Adoptive Cell Therapy for adolescent solid tumor- Children’s Hospital of Philadelphia, University of Pennsylvania, Primary Children’s Medical Center in Salt Lake City, UT Stephen Grupp MD, PhD, Michael Pulsipher MD and Carl June MD
  • Currently reviewing proposals for non resectable bulky tumor presentation

awareness + funding + research= cure